The Effect of Terlipressin in the Prevention of Type 2 Hepatorenal Syndrome by Improving Mean Arterial Pressure
NCT02489864
·
clinicaltrials.gov ↗
PHASE4
Phase
UNKNOWN
Status
30
Enrollment
OTHER
Sponsor class
Conditions
Hepatorenal Syndrome
Interventions
DRUG:
Terlipressin
Sponsor
Sun Yat-sen University